CoChat

Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs

Rehfeld, Jens F., Knop, Filip K., Asmar, Ali, Madsbad, Sten, Holst, Jens J., Asmar, Meena · 2018 · Scandinavian Journal of Gastroenterology

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Objective: Recent randomized and controlled trials of drugs derived from the gut hormone glucagon-like peptide-1 (GLP-1) show that the most frequent adverse symptoms are gastrointestinal, including gallbladder-related side effects such as cholithiasis and cholecystitis. Since the gut hormone cholecystokinin (CCK) stimulates bile secretion and regulates gallbladder motility and emptying, we examined the effect of GLP-1 on the secretion of CCK in normal subjects and patients with type 1 diabetes mellitus. Materials and methods: Plasma was sampled from 10 healthy subjects and 10 patients with diabetes. With plasma glucose concentrations clamped between 6 and 9 nmol/l, GLP-1 or saline was infused for 240 min during and after a meal. The plasma concentrations of CCK were measured with a highly specific radioimmunoassay. Results: Basal plasma concentrations of CCK were similar in the normal subjects and in the diabetes patients. During the meal, the CCK concentrations rose significantly during saline infusion, whereas the GLP-1 infusion suppressed the secretion of CCK significantly in both normal subjects and in the diabetes patients. Conclusions: The results show that GLP-1 suppresses the secretion of CCK after a meal in normal and diabetic subjects. The suppression attenuates the gallbladder contractility. Our data, therefore, offer an explanation for the increased risk of adverse gallbladder events during treatment with GLP-1-derived drugs.

Overview

Integrity signals

Registry

Crossref · 10.1080/00365521.2018.1530297

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Research works printed but not linked: 3

  1. Kumar U, 2010, Results Probl Cell Differ, 50, 137
  2. Wank SA, 1995, Am J Physiol, 269, G628
  3. Rehfeld JF, 2001, J Clin Endocrinol Metab, 86, 251

Cited by

See all 62

Metadata

Authors
Rehfeld, J. F., Knop, F. K., Asmar, A., Madsbad, S., Holst, J. J., & Asmar, M.
Affiliations
University of Copenhagen (DK)
Corresponding author
Rehfeld, Jens F.
Venue
Scandinavian Journal of Gastroenterology
Published
2018-11-19
Volume
53
Issue
12
Pages
1429-1432
ISSN
  • 0036-5521 (ISSN-L)
  • 1502-7708
OpenAlex
W2901921552
Cited by
62
References
34
Citations by year
2026: 13 · 2025: 18 · 2024: 13 · 2023: 4 · 2022: 5 · 2021: 4 · 2020: 3 · 2019: 2
FWCI
1.79
Type
journal article
Language
en
Open access
closed
Locations
  • Scandinavian Journal of Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
  • Amgen
  • AstraZeneca
  • Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Gastroenterology › Gallbladder and Bile Duct Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
cholecystokinin, glucagon-like peptide-1, GLP-1 receptor agonists, cholecystitis, gallbladder motility, type 1 diabetes, bile secretion
MeSH terms
Adult, Blood Glucose, Cholecystokinin, Diabetes Mellitus, Type 1, Female, Gallbladder, Humans, Male, Case-Control Studies, Gallbladder Emptying, Glucagon-Like Peptide 1, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. https://app.cochat.ai/papers/10.1080/00365521.2018.1530297
The paper
Rehfeld, J. F., Knop, F. K., Asmar, A., Madsbad, S., Holst, J. J., & Asmar, M. (2018). Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scandinavian Journal of Gastroenterology. https://doi.org/10.1080/00365521.2018.1530297

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.